舒利迭联合茶碱对慢性阻塞性肺疾病稳定期患者肺动脉压及右心功能的观察

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (8): 920-925.

舒利迭联合茶碱对慢性阻塞性肺疾病稳定期患者肺动脉压及右心功能的观察

黄友明¹, 王安才², 查日田¹

¹ 芜湖市第一人民医院呼吸内科,芜湖 241001,安徽;
² 皖南医学院弋矶山医院老年医学科,芜湖 241000,安徽

收稿日期:2014-05-05 修回日期:2014-07-30 出版日期:2014-08-26 发布日期:2014-08-26
作者简介:黄友明,男,硕士,副主任医师,研究方向:肺动脉高压基础与临床。 Tel: 13905538701 E-mail: hymfreey@163.com

Observation on combined seretide with theophylline on the pulmonary artery pressure and right cardiac functionin in patients with stable chronic obstructive pulmonary disease

HUANG You-ming¹, WANG An-cai², ZHA Ri-tian¹

¹ Department of Respiratory Medicine, Wuhu No.¹ People's Hospital, Wuhu 241000, Anhui, China;
² Department of Geriatrics, Wannan Medical College Affiliated Yijishan Hospital, Wuhu 241001, Anhui, China

Received:2014-05-05 Revised:2014-07-30 Online:2014-08-26 Published:2014-08-26

摘要/Abstract

摘要： 目的观察联合使用舒利迭及茶碱后,慢性阻塞性肺疾病(chronic obstructive pulmonary disease, COPD)稳定期患者肺动脉压及右心功能

关键词: 慢性阻塞性肺疾病, 舒利迭, 肺动脉高压, 右心功能

Abstract: AIM: To observe the effects of combined application of salmeterol and fluticasone propionate(seretide) powder for inhalation with theophylline sustained-release tablets on the variation of pulmonary artery pressure and right cardiac function in patients with stable pulmonary obstructive disease(COPD). METHODS: Retrospective analyses were performed in 128 COPD patients in their stable phase after therapy on hospitalization and long-term management on outpatient basis in our hospital from Sept. 2010 to Jun. 2012. after one year inhalation of secretide for determination and comparison of the right ventricular geometry parameters and Doppler parameters. RESULTS: Different baseline level of pulmonary artery pressure patient determined by echocardiography in the three groups of patients varied to a certain extent before and after therapy, yet the parameters showed no statistical difference in patients with normal pulmonary artery pressure(P>0.05). Significant pulmonary systolic pressure was observed in MPH group, with decreased right ventricular Tei index (P<0.05). In SPH group, the changes were seen concerning right ventricular Tei index, transverse RA of right atrium and anterior and posterior diameter of the RV, which were statistically different. Nevertheless, there was no statistical difference regarding the RVAW, MPA, RVESV, EVEDV, RVSV, PASP and RVEF. Enlarged right atrium and ventricle as well as widened inner diameter of the MPA to a certain degree were found in patients with mild, moderate to severe pulmonary artery pressure as compared with those in NPH group. The PASP in MPH group showed no correlation with the Tei index, and the RA and RV also had no significant correlation with the Tei index of right ventricle in SPH group. CONCLUSION: Combined utilization of seretide with theophylline can improve the right cardiac function of patients with stable COPD.

Key words: chronic obstructive pulmonary disease(COPD), Seretide (Salmeterol/fluticasone), pulmonary hypertension, ventricular function

中图分类号:

R563

黄友明, 王安才, 查日田. 舒利迭联合茶碱对慢性阻塞性肺疾病稳定期患者肺动脉压及右心功能的观察[J]. 中国临床药理学与治疗学, 2014, 19(8): 920-925.

HUANG You-ming, WANG An-cai, ZHA Ri-tian. Observation on combined seretide with theophylline on the pulmonary artery pressure and right cardiac functionin in patients with stable chronic obstructive pulmonary disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 920-925.

参考文献 19

[1]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)[J]. 中华结核和呼吸杂志, 2013, 36(4): 255-264.
[2]	Bourbeau JN.Saad. [COPD: Success needs implementing a participative care model and early treatment?][J]. Rev Mal Respir, 2013, 30(2): 93-94.
[3]	Puranik R.Long-term importance of right ventricular outflow tract patch function in patients with pulmonary regurgitation[J]. J Thorac Cardiovasc Surg, 2012, 143(5): 1103-1107.
[4]	Keene ON.Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited[J]. Eur Respir J, 2008, 32(1): 17-24.
[5]	慢性阻塞性肺疾病评估论坛专家组. 慢性阻塞性肺疾病病情严重程度评估系统在中国应用的专家共识[J]. 中华结核和呼吸杂志, 2013,36(6): 476-478.
[6]	Zervas E.Inhaled Corticosteroids in COPD: Pros and Cons[J]. Curr Drug Targets, 2013, 14(2): 192-224.
[7]	McLaughlin VV. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association[J]. J Am Coll Cardiol, 2009,53(17): 1573-1619.
[8]	Steiner MK. Interleukin-6 overexpression induces pulmonary hypertension[J]. Circ Res, 2009, 104(2): 236-244, 28p following 244.
[9]	Ahluwalia A, Hobbs AJ.Letter by ahluwalia and hobbs regarding article, “nitrate-nitrite-nitric oxide pathway in pulmonary arterial hypertension therapeutics”[J]. Circulation, 2013, 127(2): e275.
[10]	McDonald MA, Ross HJ. Trying to succeed when the right ventricle fails[J]. Curr Opin Cardiol,2009, 24(3): 239-245.
[11]	Galie N.Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2[J]. Circulation, 2008, 117(23): 3010-3019.
[12]	Boutou AK.Lung function indices for predicting mortality in chronic obstructive pulmonary disease[J]. Eur Respir J, 2013, 39(6): 81-85.
[13]	Lee J, Nordestgaard BG, Dahl M.EPHX1 polymorphisms, COPD and asthma in 47,000 individuals and in meta-analysis[J]. Eur Respir J, 2011, 37(1): 18-25.
[14]	Park HY, Man SF, Sin DD. Inhaled corticosteroids for chronic obstructive pulmonary disease[J]. BMJ, 2012, 345-346: e6843.
[15]	Cosio BG.Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD[J]. Thorax, 2009, 64(5): 424-429.
[16]	Oliver B.Low-dose theophylline does not exert its anti-inflammatory effects in mild asthma through upregulation of interleukin-10 in alveolar macrophages[J]. Allergy, 2001,56(11): 1087-1090.
[17]	Macnee W.Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease[J]. Ann Med, 2012,36(12): 756-759.
[18]	Adi HPM, Young D, Traini, et al. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers[J]. J Pharm Pharmacol, 2012, 64(9): 1245-1253.
[19]	黄茂:慢性阻塞性肺疾病规范诊治_ 呼吸胸外频道_丁香园, 2013.